Apoptosis-inducing effect of the DR5 monoclonal antibody, D-6, alone or in combination with cisplatin, on A2780 ovarian cancer cells

Jiang,Qin; Zhu,Hong; Liang,Baoquan; Huang,Yan; Li,Chunmei

doi:10.3892/mmr.2012.902

Apoptosis-inducing effect of the DR5 monoclonal antibody, D-6, alone or in combination with cisplatin, on A2780 ovarian cancer cells

Authors:
- Qin Jiang
- Hong Zhu
- Baoquan Liang
- Yan Huang
- Chunmei Li
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Abdominal Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: May 3, 2012 https://doi.org/10.3892/mmr.2012.902
Pages: 316-320

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Death receptor 5 (DR5) antibody (D-6) is a monoclonal antibody directed against DR5. The aim of this study was to explore the apoptosis-inducing effects of DR5 (D-6), alone or in combination with cisplatin, on A2780 ovarian cancer cells. The cells were treated with various concentrations of cisplatin and/or DR5 (D-6), or a combination of both. For the control group, the cells were treated only with culture medium. Twenty-four hours after the culture, the morphological changes of each group were observed under an inverted microscope. The cell growth inhibition rates were also analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, and the apoptosis was analyzed by flow cytometry. Western blotting analysis was used to detect the intracellular reaction. Our results showed that DR5 monoclonal antibody (D-6) was able to induce the apoptosis and increase the cell growth inhibition rates of ovarian cancer cells in a dose-dependent manner, and the effect was enhanced by cisplatin. There were significant morphological changes, a higher cell growth inhibition rate and apoptosis rate and lesser expression of caspase-3, 8, 9 precursors in the cells treated with both cisplatin and DR5 (D-6). The combination treatment of the DR5 monoclonal antibody (D-6) with cisplatin may be a promising treatment for ovarian cancer.

View Figures

View References

1	Bevis KS, McNally LR, Sellers JC, Della Manna D, Londono Joshi A, Amm H, Straughn JM Jr and Buchsbaum DJ: Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Gynecol Oncol. 121:193–199. 2011. View Article : Google Scholar : PubMed/NCBI
2	Estes JM, Oliver PG, Straughn JM Jr, Zhou T, Wang W, Grizzle WE, Alvarez RD, Stockard CR, LoBuglio AF and Buchsbaum DJ: Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol. 105:291–298. 2007. View Article : Google Scholar : PubMed/NCBI
3	Buchsbaum DJ, Forero-Torres A and LoBuglio AF: TRAIL-receptor antibodies as a potential cancer treatment. Future Oncol. 3:405–409. 2007. View Article : Google Scholar : PubMed/NCBI
4	Du YW, Chen JG, Bai HL, Huang HY, Wang J, Li SL, Liu GC, Jiang Q, Chai J, Zhao YP and Ma YF: A novel agonistic anti-human death receptor 5 monoclonal antibody with tumoricidal activity induces caspase- and mitochondrial-dependent apoptosis in human leukemia Jurkat cells. Cancer Biother Radiopharm. 26:143–152. 2011. View Article : Google Scholar
5	Du YW, Liu GC, Wang J, Zhao YP, Li SL, Chen JG, Jiang Q, Cai J and Ma YF: Caspase-dependent molecular mechanisms of anti-human DR5 monoclonal antibody mDRA-6 inducing apoptosis of human leukemia Jurkat cells. Ai Zheng. 28:112–116. 2009.PubMed/NCBI
6	Wu XX and Kakehi Y: Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner. Clin Cancer Res. 15:2039–2047. 2009. View Article : Google Scholar : PubMed/NCBI
7	Wang J, Lin Z, Qiao CX, Lv M, Yu M, Xiao H, Wang Q, Wang L, Feng J, Shen B, Ma Y and Li Y: Characterization of a novel anti-DR5 monoclonal antibody WD1 with the potential to induce tumor cell apoptosis. Cell Mol Immunol. 5:55–60. 2008. View Article : Google Scholar : PubMed/NCBI
8	Wang YG, Zhao KP, Chen JG, Zhang JY, Yu M, Li Y and Shen BF: The characteristic of an anti-human DR5 antibody A6. Cell Mol Immunol. 5:183–188. 2008. View Article : Google Scholar : PubMed/NCBI
9	Yagita H, Takeda K, Hayakawa Y, Smyth MJ and Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 95:777–783. 2004. View Article : Google Scholar : PubMed/NCBI
10	Guo Y, Chen C, Zheng Y, Zhang J, Tao X, Liu S, Zheng D and Liu Y: A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem. 280:41940–41952. 2005. View Article : Google Scholar : PubMed/NCBI
11	Li W, Wang S, Chen C and Zhuang G: Induction of tumor cell apoptosis via Fas/DR5. Cell Mol Immunol. 3:467–471. 2006.PubMed/NCBI
12	Kang Z, Chen JJ, Yu Y, Li B, Sun SY, Zhang B and Cao L: Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res. 17:3181–3192. 2011. View Article : Google Scholar : PubMed/NCBI
13	Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S and Fujiwara K: A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol. 19:1060–1067. 2008. View Article : Google Scholar : PubMed/NCBI
14	Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, Lawrence D, Zheng Z, Koeppen H, Stern H, Schwall R and Ashkenazi A: Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res. 14:7733–7740. 2008. View Article : Google Scholar : PubMed/NCBI
15	Duiker EW, Mom CH, de Jong S, Willemse PH, Gietema JA, van der Zee AG and de Vries EG: The clinical trail of TRAIL. Eur J Cancer. 42:2233–2240. 2006. View Article : Google Scholar : PubMed/NCBI
16	Camidge DR: Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Expert Opin Biol Ther. 8:1167–1176. 2008. View Article : Google Scholar : PubMed/NCBI
17	Liu YJ, Ma YF, Zhang J, Zhao YP, Bai HL and Li SL: Synergistic lethal effect of mDRA-6 and nimesulide on human hepatocellular cancer cell line SMMC-7721. Ai Zheng. 27:374–378. 2008.PubMed/NCBI
18	Li SL, Ma YF, Liu GC, Zhang J, Bai HL, Liu YJ and Lu F: Adriamycin enhances anti-human DR5 monoclonal antibody (mDRA-6) induced HL-60 cells apoptosis. Zhonghua Xue Ye Xue Za Zhi. 27:461–464. 2006.PubMed/NCBI
19	Ding B, Wu X, Fan W, Wu Z, Gao J, Zhang W, Ma L, Xiang W, Zhu Q, Liu J, Ding X and Gao S: Anti-DR5 monoclonal antibody-mediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int J Nanomedicine. 6:1991–2005. 2011.
20	Kendrick JE, Straughn JM Jr, Oliver PG, Wang W, Nan L, Grizzle WE, Stockard CR, Alvarez RD and Buchsbaum DJ: Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol Oncol. 108:591–597. 2008. View Article : Google Scholar : PubMed/NCBI
21	Straughn JM Jr, Oliver PG, Zhou T, Wang W, Alvarez RD, Grizzle WE and Buchsbaum DJ: Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol. 101:46–54. 2006. View Article : Google Scholar : PubMed/NCBI
22	Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, Lopez-Rios F, Fujiwara K, Matsui WH and Hidalgo M: A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther. 9:2582–2592. 2010. View Article : Google Scholar